New Parkinson's drug MF1 enters first human safety trial

NCT ID NCT07666022

Recruiting now Disease control Sponsor: University of Shizuoka Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new oral drug called MF1 in healthy adults and people with Parkinson's disease. The drug aims to block a harmful protein (alpha-synuclein) linked to Parkinson's. The main goal is to check safety and how the body processes the drug, not yet whether it works. About 58 participants will take single or multiple doses over 7–14 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MF1 (oral drug)
What this could lead to: If successful, this could point toward a treatment that slows or stops Parkinson's disease progression by targeting a key protein linked to the disease.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (58 people) and may not show any benefit. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT MALE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT MALE PARKINSON DISEASE (DISORDER)

Contacts and locations

Locations

Sumida Hospital
RECRUITING

Sumida-ku, Tokyo, 130-0004, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.